← Eichor
Condition: Who Grade Iv Gliomas Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Who Grade Iv Gliomas

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Phase 1/Phase 2 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT06630260ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV G
Phase 1 · 2 location(s) · Jonsson Comprehensive Cancer Center · NCT07089641The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.
NA · 5 location(s) · Jasper Gerritsen · NCT03861299Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Phase 1 · 1 location(s) · Plus Therapeutics · NCT05460507Implantable Microdevice In Primary Brain Tumors
EARLY_Phase 1 · 1 location(s) · Oliver Jonas · NCT04135807Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
EARLY_Phase 1 · 1 location(s) · Stony Brook University · NCT05423210Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Phase 1 · 4 location(s) · Tcelltech Inc. · NCT06482905Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Phase 2 · 27 location(s) · National Cancer Institute (NCI) · NCT05859334Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
NA · 2 location(s) · Medical University of Warsaw · NCT07488754Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06964737Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Phase 2 · 3 location(s) · Academic and Community Cancer Research United · NCT06160206Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors
Phase N/A · 1 location(s) · NanoAlvand · NCT07675070Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Phase 1 · 1 location(s) · Northwestern University · NCT06410248Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Phase 1 · 11 location(s) · Memorial Sloan Kettering Cancer Center · NCT06934889SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Phase 3 · 57 location(s) · Nuvation Bio Inc. · NCT05303519Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Phase 1 · 1 location(s) · Case Comprehensive Cancer Center · NCT05565118Targeted Pediatric High-Grade Glioma Therapy
Phase N/A · 21 location(s) · Nationwide Children's Hospital · NCT05839379Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Phase 1/Phase 2 · 3 location(s) · Plus Therapeutics · NCT01906385A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Gliobl
Phase 1 · 2 location(s) · University of Florida · NCT04573140T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas
NA · 1 location(s) · John M. Buatti · NCT07447531Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Phase 1/Phase 2 · 1 location(s) · National Institute of Neurological Disorders and Stroke (NIN · NCT07416188The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Phase N/A · 8 location(s) · Jasper Gerritsen · NCT06118723BC008-1A Injection for Recurrent CNS WHO G4 Glioma
Phase 1 · 1 location(s) · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · NCT06773481Chronic CED of TPT for Recurrent Malignant Glioma
Phase 1 · 1 location(s) · Jeffrey N. Bruce · NCT06666712Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
Phase 1 · 1 location(s) · Beijing Tiantan Hospital · NCT06253234A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma
Phase 1/Phase 2 · 16 location(s) · Debiopharm International SA · NCT05765812Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
NA · 3 location(s) · Mayo Clinic · NCT07091864An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Gliom
Phase 2 · 1 location(s) · Mayo Clinic · NCT06444412
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.